Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes… - Blood, The Journal …, 2012 - ashpublications.org
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-Year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes, M Baccarani… - …, 2012 - augusta.elsevierpure.com
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
[PDF][PDF] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes, M Baccarani… - BLOOD, 2012 - researchgate.net
(CCyR), confirmed CCyR (primary end point), and major molecular response (MMR). Here,
24-month data are presented. Cumulative response rates by 24 months in dasatinib and …
24-month data are presented. Cumulative response rates by 24 months in dasatinib and …
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes, M Baccarani… - …, 2012 - pubmed.ncbi.nlm.nih.gov
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes, M Baccarani… - Blood, 2012 - research.rug.nl
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
[PDF][PDF] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes, M Baccarani… - BLOOD, 2012 - academia.edu
(CCyR), confirmed CCyR (primary end point), and major molecular response (MMR). Here,
24-month data are presented. Cumulative response rates by 24 months in dasatinib and …
24-month data are presented. Cumulative response rates by 24 months in dasatinib and …
[引用][C] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM KANTARJIAN, NP SHAH, C PAVLOVSKY… - Blood, 2012 - pascal-francis.inist.fr
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year
follow-up from a randomized phase 3 trial (DASISION) CNRS Inist Pascal-Francis CNRS …
follow-up from a randomized phase 3 trial (DASISION) CNRS Inist Pascal-Francis CNRS …
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
HM Kantarjian, NP Shah, JE Cortes, M Baccarani… - Blood, 2011 - europepmc.org
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes, M Baccarani… - Blood, 2012 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Dasatinib is a highly potent BCR-ABL inhibitor
with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic …
with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic …
[HTML][HTML] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes, M Baccarani… - Blood, 2012 - Elsevier
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …